Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASTAL randomized phase II proof-of-concept study of tocilizumab added to neoadjuvant chemoradiation in esophageal adenocarcinoma
NL-OMON20876Phase 2Not yet recruiting
- Sponsor
- Oncode Institute
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Oncode Institute. Primary endpoint: Pathological response by Mandard criteria. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON20876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20876.